Journal article · 2023
Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making.
Journal of Clinical Oncology, 41(16_suppl), e13646 · Published 1 June 2023 · DOI 10.1200/jco.2023.41.16_suppl.e13646
In brief
“Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making.” is a 2023 journal article by Ali Cimen and 6 co-authors, published in Journal of Clinical Oncology. OpenAlex counts 1 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 1
- Most cited in
- 2025 (1)
- Authors
- 7
Abstract
e13646 Background: The ability of novel cancer drugs to extend patients’ overall survival (OS) has been key to determining their approval and access conditions. However, in some disease settings, OS can have limitations: delayed access due to the time required to collect mature OS data; confounding from subsequent treatment lines; and poor ability to reflect… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cimen, A., Nelsen, L. M., Fameli, A., Paulsson, T., Altimari, S., Gutiérrez, B., & Harrison, N. (2023). Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making. Journal of Clinical Oncology, 41(16_suppl), e13646. https://doi.org/10.1200/jco.2023.41.16_suppl.e13646
MLA 9
Cimen, Ali, et al. “Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making.” Journal of Clinical Oncology, vol. 41, no. 16_suppl, 2023, p. e13646. https://doi.org/10.1200/jco.2023.41.16_suppl.e13646.
Chicago
Cimen, Ali, Linda M. Nelsen, A. Fameli, Thomas Paulsson, Shannon Altimari, Benjamín Gutiérrez, and Nick Harrison. 2023. “Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making.” Journal of Clinical Oncology 41 (16_suppl): e13646. https://doi.org/10.1200/jco.2023.41.16_suppl.e13646.
Harvard
Cimen, A. et al. (2023) ‘Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making.’, Journal of Clinical Oncology, 41(16_suppl), p. e13646. doi:10.1200/jco.2023.41.16_suppl.e13646.
IEEE
A. Cimen et al., “Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making.,” Journal of Clinical Oncology, vol. 41, no. 16_suppl, p. e13646, 2023, doi: 10.1200/jco.2023.41.16_suppl.e13646.
BibTeX
@article{cimen2023shifting,
title = {{Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making.}},
author = {Cimen, Ali and Nelsen, Linda M. and Fameli, A. and Paulsson, Thomas and Altimari, Shannon and Gutiérrez, Benjamín and Harrison, Nick},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {16_suppl},
pages = {e13646},
doi = {10.1200/jco.2023.41.16_suppl.e13646},
url = {https://doi.org/10.1200/jco.2023.41.16_suppl.e13646}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- patient-reported outcomes
- overall survival
- surrogate endpoints
- stakeholder perspectives
- perceived value
- payers
- patient associations
- disease burden
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
Cimen, A., Nelsen, L. M., Fameli, A., Paulsson, T., Altimari, S., Gutiérrez, B., & Harrison, N. (2023). Shifting perspectives on the value of non-OS endpoints and PROs: Considerations across stakeholder groups to support oncology HTA decision-making. Journal of Clinical Oncology, 41(16_suppl), e13646. https://doi.org/10.1200/jco.2023.41.16_suppl.e13646
How many times has this paper been cited?
1 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Ali Cimen, Linda M. Nelsen, A. Fameli, Thomas Paulsson, Shannon Altimari, Benjamín Gutiérrez, Nick Harrison.
What is the DOI of this paper?
10.1200/jco.2023.41.16_suppl.e13646, permanently at https://doi.org/10.1200/jco.2023.41.16_suppl.e13646. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.